AR036034A1 - Compuestos de pirazol fusionado, de aplicacion en el tratamiento de cancer y de enfermedades medidas por la superproduccion de factores tgf-beta; formulaciones farmaceuticas que incluyen dichos compuestos de pirazol fusionado como agente activo; uso de los compuestos mencionados para preparar medica - Google Patents
Compuestos de pirazol fusionado, de aplicacion en el tratamiento de cancer y de enfermedades medidas por la superproduccion de factores tgf-beta; formulaciones farmaceuticas que incluyen dichos compuestos de pirazol fusionado como agente activo; uso de los compuestos mencionados para preparar medicaInfo
- Publication number
- AR036034A1 AR036034A1 ARP020101974A ARP020101974A AR036034A1 AR 036034 A1 AR036034 A1 AR 036034A1 AR P020101974 A ARP020101974 A AR P020101974A AR P020101974 A ARP020101974 A AR P020101974A AR 036034 A1 AR036034 A1 AR 036034A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- hydrogen
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Compuestos de pirazol y, respectivamente, de pirazol fusionado de fórmula (1) en donde el grupo de fórmula (2) es un anillo saturado de cuatro, cinco o seis miembros y X es C, O ó S; R1 es fenilo sustituido o no sustituido; piridina sustituida o no sustituida; N-óxido de piridina; N-óxido de piridina sustituido o no sustituido; quinolina sustituida o no sustituida; N-óxido de quinolina; N-óxido de quinolina sustituido o no sustituido; naftiridina sustituida o no sustituida; pirazina sustituida o no sustituida; furilo; tiazolilo; imidazolilo sustituido o no sustituido; pirazolilo sustituido o no sustituido; o tiofenilo sustituido o no sustituido; en donde la sustitución puede ser una o más de las siguientes: alquilo C1-6; alquenilo C2-6; alquinilo C2-6; alcoxi C1-6; alqueniloxi C2-6; alquiniloxi C2-6; alquiltio C1-6; alquilsulfinilo C1-6; alquilsulfonilo C1-6; alquilamino C1-6, di-[alquil C1-6]amino; alcoxicarbonilo C1-6; N-alquil C1-6-carbamoilo; N,N-di-[alquil C1-6]carbamoilo; alcanoílo C2-6; alcanoiloxi C2-6; alcanoilamino C2-6; N-alquil C1-6-alcanoilamino C2-6; alquenoilamino C3-6; N-alquil C1-6-alquenoilamino C3-6; alquinoilamino C3-6; N-alquil C1-6-alquinoilamino C3-6; N-alquilsulfamoilo C1-6; N,N-di-[alquil C1-6]sulfamoilo; alcansulfonilamino C1-6; N-alquil C1-6-alcansulfonilamino C1-6; carboxamida; etileno; tiofenilo; aminofenilo; trifluorometilo; halo; trifluorometoxi; hidroximetilo; N-pirrolidino; N-morfolino; feniltio; dialquilaminometilo C1-4; metoxifenilo; amino; hidroxi; carboxilo; fenilo; arilalquilo; R2 es quinolina sustituida o no sustituida; N-óxido de quinolina sustituido o no sustituido; fenilo sustituido o no sustituido; naftaleno sustituido o no sustituido; piridina sustituida o no sustituida; N-óxido de piridina sustituido o no sustituido; quinazolina sustituida o no sustituida; cinolina sustituida o no sustituida; benzodioxol sustituido o no sustituido; benzodioxano sustituido o no sustituido; pirimidina sustituida o no sustituida; benzotiofeno sustituido o no sustituido; o fenantroleno sustituido o no sustituido; en donde la sustitución puede ser en forma independiente uno o más de los siguientes: hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilhaluro C1-6, alcoxi C1-6,alqueniloxi C2-6, alquiniloxi C2-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di[alquil C1-6]amino, alcoxicarbonilo C1-6, N-alquilcarbamoilo C1-6, N,N-di[alquil C1-6]carbamoilo, aminooxi, N-alquil C1-6-aminooxi, N,N-di[alquil C1-6]aminooxi, alcanoílo C2-6, alcanoiloxi C2-6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, alquenoilamino C3-6, N-alquil C1-6-alquenoilamino C3-6, alquinoilamino C3-6, N-alquil C1-6-alquinoilamino C3-6, sulfamoilo, N-alquilsulfamoilo C1-6, N,N-di[alquil C1-6]sulfamoilo, alcansulfonilamino C1-6, N-alquil C1-6-alcansulfonilamino C1-6, carboxamida, etileno, fenilo, tiofenilo, aminofenilo, feniltio, halo, ciano, piridinilo, arilalquilo, hidroxi, N-pirrolidino, N-morfolino, carboxilo, [5-fenil-1,2,4-oxadiazol-3-il]metoxi, 6-metil-piridazin-3-iloxi, (5-oxo-2-pirrolidinil)metoxi, 2-(4,5-dihidro-1H-imidazolilo), N,N-dialquilcarbamoiloxi, 1-hidroxi-1-metiletilo, 4-fluorofenilo, 3,4-metilendioxifenilo, trifluorometilo, trifluorometoxi, o un grupo de la fórmula X1-(CH2)n(CR10R16)(CH2)m-Q1, en donde: X1 es O, N, S, SO2, NR13, C(O), ó enlace; Q1 es hidrógeno, fenilo, 5-(2,2-difluoro-1,3-benzodioxolilo), C(O)Q5, ó piridilo cuando m y n son independientemente 0-2, excepto cuando uno de ellos es cero, el otro no puede ser 0; Q1 es OR11, NR11R12, halo, N-morfolino, N-piperazino-N'R13, N-imidazolilo, N-pirazolilo, N-triazolilo, N-(4-piperidinilpiperidina), SO2R14, SOR14, NHSO2R15, acetamido, N-ftalimido, N-oxazolidino, N-imidazolino, N-benzoxazolidino, N-pirrolidinonilo, N(N'-metilbencimidazolino), N,N-dialquilamino C1-4-alcoxi C1-4, N-bencimidazolino; cuando m y n son independientemente 0-2, pero uno o el otro de m ó n no es 0; Q5 es hidroxi, metoxi, amino, dietilamino, dimetilamino; R10 es hidrógeno, halo, alquilo C1-6; R11 y R12 son independientemente hidrógeno, alquilo C1-6, alcoxi C1-6, arilalquilo, cicloalquilo C3-8, cicloalquilmetilo C3-8, 4-(N-metilpiperidinilo), piridilo, ó R11 y R10 pueden tomarse juntos para formar un anillo de 4, 5, 6 ó 7 miembros, ó R11 y R12 pueden tomarse juntos para formar un anillo de 3, 4, 5, 6 ó 7 miembros; R13 es hidrógeno, alquilo C1-6, 2-metoxifenilo, 2-piridimidinilo; R14 es 2-pirimidinilo, N-metil-2-imidazolilo, 4-clorofenilo, 2-piridilmetilo; R15 es alquilo C1-6, N-metil-4-imidazolilo; R16 es hidrógeno, halo, arilalquilo, arilo o un grupo de fórmula -C(O)-NR20-(CH2)o(CR21R22)(CH2)p-Q2, donde: Q2 es hidrógeno, 4-imidazolilo, ó C(O)NR24R25 cuando o y p son independientemente 0-2; Q2 es OR23, NR24R25 ó N-morfolino, cuando o y p son independientemente 0-2, pero uno o el otro de o ó p no es 0; R20 es hidrógeno o alquilo C1-6; R21 es hidrógeno, alquilo C1-6, ó R21 y R20 pueden tomarse juntos para formar un anillo de 4, 5, 6 ó 7 miembros; R22 es hidrógeno, alquilo C1-6, arilalquilo, arilo, ó R21 y R22 pueden tomarse juntos para ser un anillo de 3, 4, 5, 6, 7 miembros; R23 es hidrógeno o alquilo C1-6; R24 es hidrógeno, alquilo C1-6, ó R24 y R25 pueden tomarse juntos para formar un anillo de 3, 4, 5, 6 ó 7 miembros, ó R24 y R20 pueden tomarse juntos para formar un anillo de 6 ó 7 miembros; R25 es hidrógeno, alquilo C1-6, o acetilo, o un grupo de la fórmula -C(O)NR30R31, en donde: R30 es hidrógeno, o alquilo C1-6; R31 es hidrógeno, alquilo C1-6, 2-piridilo, piridilmetilo, amino, o hidroxi, o un grupo de la fórmula -NR32R33, en donde: R32 y R33 son cada uno en forma independiente hidrógeno, alquilo C1-6, acetilo, alquilsulfonilo C1-4, ó R32 y R33 pueden tomarse juntos para formar un anillo de 4, 5, 6 ó 7 miembros, o un grupo de fórmula -NR35C(O)X2(CH2)q-Q3, en donde: X2 es CH2, O ó N; q es 2-3 excepto cuando Q3 es un enlace, q es 0-3; Q3 es NR36R37 u OR38, y R35 es hidrógeno, o R35 y Q3 pueden tomarse juntos para formar un anillo de 5 miembros; R36, R37 y R38 son cada uno en forma independiente hidrógeno, o alquilo C1-6 o un fenoxi sustituido con X3, en donde X3 es ciano, carboxamida, N,N-dimetilcarboxamida, N,N-dimetiltiocarboxamida, N,N-dimetilaminometilo, 4-metilpiperazin-1-il-metilo o carboxilato, o un grupo de la fórmula -O-CH2-C(O)NR40-(CH2)r-Q6, en donde: Q6 es NR41R42; r es 2-3; R40 es hidrógeno, o alquilo C1-6; R41 y R42 son hidrógeno, alquilo C1-6, ó R41 y R40 pueden tomarse juntos para formar un anillo de 6 ó 7 miembros, o un grupo de la fórmula -CH=CH-C(O)Q7 en donde: Q7 es hidroxi, metoxi, dimetilamino, o N-piperidinilo; con la condición que cuando uno de R1 ó R2 es fenilo sustituido o no sustituido, el otro no puede ser fenilo sustituido o no sustituido o tiofen-2-ilo, y con la condición que cuando R2 es quinolin-4-ilo, la sustitución en la posición 7 de quinolina no puede incluir arilo, heteroarilo, arilo fusionado, o heteroarilo fusionado; k es 1-8; R3 es uno o más de los siguientes: hidrógeno, alquilo C1-4; alquilhidroxi C1-4, hidroxi, N,N-dialquilamino C1-4-alcoxi C1-4; benciloximetilo; feniloximetilo; oxo; carboxilo; alquilarilo C1-4; benciloxi; acetoxi; aminoalquilo C1-4; alquenilo C2-4; halo; -O-alquilo C1-4. clorofenetilo; acetonitrilo; fenilo sustituido o no sustituido; en donde la sustitución puede ser uno o más de los siguientes: alcoxi C1-6, halo, carboxi o alcoxicarbonilo C1-6; y las sales, ésteres y profármacos farmacéuticamente aceptables de los mismos. Los compuestos tienen aplicación en el tratamiento del cáncer y de enfermedades mediadas por la superproducción de factores TGF-beta. Formulaciones farmacéuticas que incluyen dichos compuestos como agente activo, uso de los compuestos mencionados para preparar medicamentos para el tratamiento de cáncer y métodos para tratar cáncer utilizando dichos compuestos, sus sales ésteres y sus profármacos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29346401P | 2001-05-24 | 2001-05-24 | |
PCT/US2002/011884 WO2002094833A1 (en) | 2001-05-24 | 2002-05-13 | Novel pyrrole derivatives as pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036034A1 true AR036034A1 (es) | 2004-08-04 |
Family
ID=23129192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101974A AR036034A1 (es) | 2001-05-24 | 2002-05-27 | Compuestos de pirazol fusionado, de aplicacion en el tratamiento de cancer y de enfermedades medidas por la superproduccion de factores tgf-beta; formulaciones farmaceuticas que incluyen dichos compuestos de pirazol fusionado como agente activo; uso de los compuestos mencionados para preparar medica |
Country Status (38)
Country | Link |
---|---|
US (1) | US7087626B2 (es) |
EP (1) | EP1397364B1 (es) |
JP (2) | JP4519407B2 (es) |
KR (1) | KR100861630B1 (es) |
CN (2) | CN1269820C (es) |
AR (1) | AR036034A1 (es) |
AT (1) | ATE368041T1 (es) |
AU (1) | AU2002339268B2 (es) |
BR (1) | BR0209939A (es) |
CA (1) | CA2446820C (es) |
CO (1) | CO5540282A2 (es) |
CY (1) | CY1106871T1 (es) |
CZ (1) | CZ303808B6 (es) |
DE (1) | DE60221392T2 (es) |
DK (1) | DK1397364T3 (es) |
DZ (1) | DZ3506A1 (es) |
EA (1) | EA007782B1 (es) |
EC (1) | ECSP034859A (es) |
EG (1) | EG25614A (es) |
ES (1) | ES2289116T3 (es) |
HK (1) | HK1064375A1 (es) |
HR (1) | HRP20030961B1 (es) |
HU (1) | HU228844B1 (es) |
IL (2) | IL158512A0 (es) |
MX (1) | MXPA03010630A (es) |
MY (1) | MY134586A (es) |
NO (1) | NO326701B1 (es) |
NZ (1) | NZ528525A (es) |
PE (1) | PE20030117A1 (es) |
PL (1) | PL221339B1 (es) |
PT (1) | PT1397364E (es) |
SI (1) | SI1397364T1 (es) |
SK (1) | SK287857B6 (es) |
SV (1) | SV2003001054A (es) |
TW (1) | TWI329644B (es) |
UA (1) | UA76461C2 (es) |
WO (1) | WO2002094833A1 (es) |
ZA (1) | ZA200308546B (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002339268B2 (en) * | 2001-05-24 | 2007-05-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
JP2005516916A (ja) * | 2001-12-11 | 2005-06-09 | スミスクライン ビーチャム コーポレーション | 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体 |
WO2004026871A1 (en) * | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
CA2506799A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
US20060079680A1 (en) * | 2002-11-22 | 2006-04-13 | Eli Lilly And Company Patent Division | Pyrazoloazepine compounds as pharmaceutical agents |
AU2003290734A1 (en) * | 2002-11-27 | 2004-06-23 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
US7511065B2 (en) * | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US7977354B2 (en) | 2005-04-01 | 2011-07-12 | Insa Rouen | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
WO2007018818A1 (en) * | 2005-07-22 | 2007-02-15 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Hsp90活性を調節するピラゾール化合物 |
WO2007076127A2 (en) * | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
US8034834B2 (en) * | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
EP2918288B1 (en) | 2006-10-03 | 2017-08-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
PL2217600T3 (pl) | 2007-12-12 | 2013-04-30 | Du Pont | Grzybobójcze pirazole bicykliczne |
WO2010070060A1 (en) * | 2008-12-19 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
EP2419105A4 (en) * | 2009-04-17 | 2012-09-12 | Summa Health Systems Llc | USE OF TRANSFORMATION OF GROWTH FACTOR B RECEPTOR INHIBITORS TO SUPPRESS OCULAR HEALING |
AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
EP2402340A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2401915A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402338A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402339A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
WO2012138945A1 (en) | 2011-04-08 | 2012-10-11 | Aestus Therapeutics, Inc. | Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta |
US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
IN2014DN03049A (es) | 2011-10-26 | 2015-05-15 | Seattle Childrens Res Inst | |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
EP2776025A1 (en) | 2011-11-02 | 2014-09-17 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
JP6449772B2 (ja) | 2012-10-05 | 2019-01-09 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | ヒト抗vegfr2/kdr抗体 |
TWI443096B (zh) | 2012-12-18 | 2014-07-01 | Ind Tech Res Inst | 3-(5-(4-(3-氟丙基)哌嗪-1-基)苯並咪唑-2-基)-1-氮雜薁-2-酮之單水合晶型及其製備方法與藥學組成物 |
US9879004B2 (en) * | 2013-02-07 | 2018-01-30 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 |
ES2786925T3 (es) | 2013-03-14 | 2020-10-14 | Brigham & Womens Hospital Inc | Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales |
US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
UA121309C2 (uk) | 2014-02-03 | 2020-05-12 | Вітае Фармасьютікалс, Ллс | Дигідропіролопіридинові інгібітори ror-гамма |
CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10822337B2 (en) * | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
MX2018006223A (es) * | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Moduladores de ror-gamma. |
WO2017120543A1 (en) | 2016-01-08 | 2017-07-13 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
DK3429603T3 (da) | 2016-03-15 | 2022-03-14 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller |
DK3470409T3 (da) * | 2016-06-13 | 2020-05-11 | Genfleet Therapeutics Shanghai Inc | Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer |
EP3492461A4 (en) | 2016-07-29 | 2020-02-12 | Shanghai Yingli Pharmaceutical Co. Ltd. | NITROGEN HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF |
KR20190104359A (ko) | 2016-12-30 | 2019-09-09 | 프리퀀시 테라퓨틱스, 인크. | 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법 |
EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PL3691620T3 (pl) | 2017-10-05 | 2022-11-21 | Fulcrum Therapeutics, Inc. | Inhibitory kinazy p38 zmniejszają poziom ekspresji genu dux4 i dalszych genów do leczenia fshd |
BR112020007067A2 (pt) | 2017-10-11 | 2020-10-06 | F. Hoffmann-La Roche Ag | compostos bicíclicos para uso como inibidores rip1 quinase |
JP2021035911A (ja) * | 2017-11-15 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体及びその医薬用途 |
BR112020011602A2 (pt) * | 2017-12-13 | 2020-12-08 | Genfleet Therapeutics (Shanghai) Inc. | Forma cristalina e forma salina de um inibidor tgf-ssri e método de preparação dos mesmos |
CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
WO2019183245A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
US20210309679A1 (en) * | 2018-07-23 | 2021-10-07 | Guangzhou Othrotx Co., Ltd. | Bisphosphonate drug conjugates |
WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
AU2019321641A1 (en) | 2018-08-17 | 2021-04-15 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating Jag-1 |
WO2020088526A1 (zh) * | 2018-10-31 | 2020-05-07 | 南京明德新药研发有限公司 | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 |
EP3883556A2 (en) | 2018-11-22 | 2021-09-29 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Tgf? inhibitor and prodrugs |
CN113348167A (zh) | 2018-12-27 | 2021-09-03 | 奈可萨斯医药有限公司 | 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物 |
CN113508111A (zh) | 2018-12-31 | 2021-10-15 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
EP3922631A4 (en) * | 2019-01-24 | 2022-10-26 | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS AS A TGF-BETA R1 KINASE INHIBITOR |
US20220073494A1 (en) * | 2019-01-31 | 2022-03-10 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020248908A1 (zh) * | 2019-06-10 | 2020-12-17 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
CN114867723B (zh) * | 2020-07-23 | 2023-05-30 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
WO2022063050A1 (zh) | 2020-09-28 | 2022-03-31 | 四川科伦博泰生物医药股份有限公司 | 吡唑类化合物及其制备方法和用途 |
CN115703750A (zh) * | 2021-08-17 | 2023-02-17 | 黑龙江华瑞生物科技有限公司 | 一种1-氨基-4-甲基哌嗪的提取纯化方法 |
CN114249742B (zh) * | 2021-11-22 | 2022-11-01 | 郑州大学 | 一种光气探针、荧光书写检测笔及其在光气检测中的应用 |
CN115969801B (zh) * | 2023-03-21 | 2023-08-25 | 劲方医药科技(上海)有限公司 | 用于癌症的药物组合物及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
JPH07507796A (ja) * | 1992-06-17 | 1995-08-31 | ファルマシア・アンド・アップジョン・カンパニー | 抗−アテローム性動脈硬化剤および抗−高コレステロール血症剤として有用なピリジノ−,ピロリジノ−,およびアゼピノ−置換オキシム類 |
GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
CA2144330A1 (en) * | 1993-07-27 | 1995-02-09 | Fumio Suzuki | A therapeutic agent for parkinson's disease |
US5358947A (en) * | 1993-09-13 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones |
AUPN419395A0 (en) * | 1995-07-17 | 1995-08-10 | Treescope Development Co. Pty. Ltd. | Plant protector |
FR2746306B1 (fr) * | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture |
EE9900527A (et) | 1997-05-22 | 2000-06-15 | G.D. Searle & Co. | Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid |
FR2772379B1 (fr) * | 1997-12-16 | 2000-02-11 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles |
GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
WO2000044743A1 (fr) * | 1999-01-28 | 2000-08-03 | Nippon Shinyaku Co., Ltd. | Derives d'amides et compositions de medicaments |
ES2187473T3 (es) | 1999-04-09 | 2003-06-16 | Smithkline Beecham Corp | Triarylimidazoles. |
ES2222919T3 (es) * | 1999-08-27 | 2005-02-16 | Abbott Laboratories | Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2. |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US7125887B2 (en) * | 2000-10-11 | 2006-10-24 | Merck & Co., Inc. | Pyrrolidine modulators of CCR5 chemokine receptor activity |
EP1355903B1 (en) | 2001-02-02 | 2005-03-16 | SmithKline Beecham Corporation | Pyrazole derivatives against tgf overexpression |
AU2002339268B2 (en) * | 2001-05-24 | 2007-05-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
EP1633912B1 (en) * | 2003-05-28 | 2014-07-16 | Oerlikon Textile GmbH & Co. KG | A method and a fibre distributor for air-laying fibres |
JP4882198B2 (ja) | 2003-09-25 | 2012-02-22 | 日産自動車株式会社 | 燃料電池システム |
-
2002
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/en active IP Right Grant
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 CA CA2446820A patent/CA2446820C/en not_active Expired - Fee Related
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active IP Right Cessation
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 EP EP02744115A patent/EP1397364B1/en not_active Expired - Lifetime
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
-
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
-
2004
- 2004-09-15 HK HK04107054A patent/HK1064375A1/xx not_active IP Right Cessation
-
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
-
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036034A1 (es) | Compuestos de pirazol fusionado, de aplicacion en el tratamiento de cancer y de enfermedades medidas por la superproduccion de factores tgf-beta; formulaciones farmaceuticas que incluyen dichos compuestos de pirazol fusionado como agente activo; uso de los compuestos mencionados para preparar medica | |
JP7182526B2 (ja) | P2x3および/またはp2x2/3化合物ならびに方法 | |
US20210145832A1 (en) | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | |
US20230183209A1 (en) | Cereblon ligands and bifunctional compounds comprising the same | |
JP2020504766A5 (es) | ||
JP2020506922A5 (es) | ||
CZ291791B6 (cs) | Amidy pyridylalkenové a pyridylalkinové kyseliny jako cytostatika a imunosupresiva | |
CA2295087A1 (en) | Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | |
IL173397A0 (en) | Pyridyl derivatives and their use as therapeutic agents | |
MX2012012972A (es) | Compuestos de picolinamida y pirimidin-4-carboxamida, proceso para su preparacion y composicion farmaceutica que comprende los mismos. | |
GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
US11339169B2 (en) | P2X3 and/or P2X2/3 compounds and methods | |
ES2333802T3 (es) | Inhibidores no nucleicos de transcriptasa inversa. | |
RU2013132930A (ru) | Производное пиразола | |
ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
RU2005103618A (ru) | Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина | |
US20160311829A1 (en) | Wnt pathway modulators | |
PL315035A1 (en) | Cyclic amide derivatives as antagonistic substances in respect to neurokinin a | |
JP2023539663A (ja) | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 | |
HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
TW429256B (en) | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives | |
MY113446A (en) | 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2-one derivatives | |
UA66842C2 (uk) | Похідні піридину як інгібітори pde iv | |
US9227955B2 (en) | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | |
RU2011140404A (ru) | Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |